The use of
phosphate-binding agents, singly or in combination, is associated with reduced
mortality in patients with chronic kidney disease as per the results of COSMOS
trial (Current management Of Secondary hyperparathyroidism: A Multicenter
Observational Study).
COSMOS was
a 3-year follow-up, multicenter, open-cohort, prospective study of adult
chronic hemodialysis patients with no previous kidney transplant from 227
dialysis centers from 20 European countries.
The
analysis, published in the July 3, 2013 issue of Kidney International, included
6,300 patients.
Patients
prescribed phosphate-binding agents were found to have 29% lower all-cause
mortality and 22% lower cardiovascular mortality.
All types
of phosphate-binding agents were effective with three exceptions:
aluminum-containing phosphate binder on its own, combinations of
calcium-containing binders with aluminum, and combinations of
calcium-containing binders with other phosphate binders.
